Is Minimal Residual Disease Monitoring Clinically Relevant in Adults with Acute Myelogenous Leukemia?
- 6 April 2013
- journal article
- research article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 8 (2) , 109-115
Abstract
In the past year, there has been increasing attention towards understanding the clinical relevance of minimal residual disease (MRD) assessment. The monitoring of MRD levels at various stages of therapy has considerable potential to impact the guidance of treatment for AML patients and improve outcomes. Thus, efforts have increased to address important concerns regarding MRD measurements. These concerns include: (1) what should be monitored; (2) what methodologies should be used; (3) whether such methodologies are standardized across laboratories; (4) how prognostic levels are defined; (5) when MRD should be monitored; and (6) what treatment options are available for MRD positive patients. In this review, we will discuss the methodologies available for MRD and the studies available to date aiming to address the concerns around the use of MRD measurements for AML patientsKeywords
This publication has 51 references indexed in Scilit:
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemiaBlood, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trialLeukemia, 2011
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialThe Lancet Oncology, 2010
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences, 2010
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemiaProceedings of the National Academy of Sciences, 2007
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997